SCHEMBL21641014

SCHEMBL21641014

O=C(CCCO)NC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
SLC6A9 P48067 1/20 0.44
LMNA P02545 1/20 0.43
EPHX2 P34913 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
EPHX1 P07099 1/20 0.42
AGTR2 P50052 1/20 0.41
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21640928 0.82 SLC6A9 (0.50) MAPTSLC6A9LMNANPSR1CNR1
SCHEMBL4793162 0.79 NPSR1 (0.50) MAPTSLC6A9NPSR1CNR1CNR2
SCHEMBL21640667 0.78 CYP3A4 (0.52) MAPTSLC6A9NPSR1CNR1CNR2
SCHEMBL377735 0.77 KMT2A (0.51) SLC6A9NPSR1CNR1CNR2HTT
SCHEMBL1744817 0.75 NPSR1 (0.49) MAPTSLC6A9NPSR1CNR1CNR2
SCHEMBL13889298 0.74 SLC6A9 (0.51) MAPTSLC6A9LMNANPSR1CNR1
SCHEMBL27717381 0.74 SLC6A9 (0.48) MAPTSLC6A9NPSR1CNR1CNR2
SCHEMBL21640167 0.74 SLC6A9 (0.43) MAPTSLC6A9LMNANPSR1CNR1
SCHEMBL27717458 0.73 CACNA1A (0.49) SLC6A9NPSR1CNR1CNR2HTT
SCHEMBL5283241 0.71 DPP4 (0.41) SLC6A9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2022-03-29 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 MAPT 4722/4885SLC6A9 2277/4885LMNA 4119/4885
US-11286255-B2 Pyridone carboxylic acid derivative or salt thereof RARA, RAB10, RABL6 MAPT 4766/4885SLC6A9 2300/4885LMNA 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.